Research on approaches to improving cancer patients perioperative immunity and reducing postsurgical cancer recurrence

Perioperative regulatory T cell responses to propranolol or parecoxib administration in breast cance

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005271

Enrollment

Unknown

Registered

2014-09-19

Start date

2014-05-19

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

control :surgery

propranolol:surgery and propranolol

parecoxib :surgery and parecoxib

propranolol and parecoxib:surgery, propranolol and parecoxib

Eligibility

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were modified radical mastectomy for primary breast cancer diagnosed by biopsy, aged between 25-65 years in the Third Xiangya Hospital.

Exclusion criteria

Exclusion criteria: Exclusion criteria were previous breast cancer surgery (except diagnostic biopsy), inflammatory breast cancer, received chemotherapy and/or radiotherapy before surgery, ASA (American Society of Anesthesiologists) Physical Status III-IV or greater, complicated with diseases of immune system or endocrine system, long-term medication with effect on immune or endocrine system, and contraindications about propranolol or parecoxib.

Design outcomes

Primary

Measure	Time frame
the percentage of Tregs /CD4 T cell;real-time PCR of Foxp3;catecholamine;prostaglandin;IFN-gama Elispot;	—

Countries

China

Contacts

Public ContactWen Ouyang

oyw_xysyy@163.com+86 13974934441

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026